AbbVie Inc. $ABBV Shares Sold by Carolina Wealth Advisors LLC

Carolina Wealth Advisors LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 98.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 620 shares of the company’s stock after selling 38,267 shares during the quarter. Carolina Wealth Advisors LLC’s holdings in AbbVie were worth $144,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Hobart Private Capital LLC grew its position in AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after acquiring an additional 48 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock valued at $848,000 after purchasing an additional 51 shares during the period. FF Advisors LLC grew its holdings in AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Landaas & Co. WI ADV increased its stake in AbbVie by 1.1% during the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after buying an additional 53 shares during the period. Finally, Bernardo Wealth Planning LLC lifted its holdings in AbbVie by 2.9% in the 2nd quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock worth $354,000 after buying an additional 53 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. UBS Group upped their target price on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Up 0.3%

ABBV stock opened at $224.32 on Thursday. The firm has a market cap of $396.47 billion, a price-to-earnings ratio of 169.94, a PEG ratio of 1.27 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a fifty day moving average price of $226.87 and a two-hundred day moving average price of $210.61. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business posted $3.00 EPS. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.